SCHEMBL19690341

SCHEMBL19690341

CC(C)(C)OC(=O)N1CCOc2c(Br)cccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.47
UCHL1 P09936 1/20 0.46
KDM1A O60341 1/20 0.43
HDAC1 Q13547 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
USP30 Q70CQ3 1/20 0.39
BCHE P06276 1/20 0.38
EGFR P00533 1/20 0.37
BTK Q06187 1/20 0.37
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
MAPT P10636 1/20 0.36
NR1H2 P55055 2/20 0.35
NR1H3 Q13133 1/20 0.35
MEN1 O00255 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14243176 0.93 UCHL1 (0.47) NOTUMUCHL1KDM1AHDAC1HDAC6
SCHEMBL29753484 0.84 HDAC1 (0.47) NOTUMKDM1AHDAC1HDAC6USP30
Potassium Ion SCHEMBL30896870 0.84 NOTUM (0.46) NOTUMUCHL1KDM1AHDAC1HDAC6
SCHEMBL306243 0.84 NOTUM (0.46) NOTUMUCHL1KDM1AHDAC1HDAC6
SCHEMBL29753309 0.84 NOTUM (0.46) NOTUMUCHL1KDM1AHDAC1HDAC6
SCHEMBL21917298 0.83 NOTUM (0.48) NOTUMBCHEEGFRSMN1; SMN2MAPT
SCHEMBL24427963 0.82 USP30 (0.38) NOTUMUCHL1KDM1AHDAC1HDAC6
SCHEMBL307163 0.82 NOTUM (0.45) NOTUMUCHL1KDM1AHDAC1HDAC6
SCHEMBL29753157 0.82 NOTUM (0.45) NOTUMUCHL1KDM1AHDAC1HDAC6
SCHEMBL29753660 0.81 NOTUM (0.47) NOTUMUCHL1KDM1AHDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144788-A1 COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF UBIX THERAPEUTICS, INC. (KR) 2026-05-28 US disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
EP-4606799-A1 COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF Ubix Therapeutics, Inc. (KR) 2025-08-27 EP disclosed
EP-4536656-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 Therapeutics, Inc. (US) 2025-04-16 EP disclosed
WO-2024085699-A1 COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF 주식회사 유빅스테라퓨틱스 2024-04-25 WO disclosed
EP-3466934-B1 SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER TAIHO PHARMACEUTICAL CO LTD (JP) 2024-03-27 EP disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
EP-3976608-B1 THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2023-11-08 EP disclosed
EP-3209652-B1 TRICYCLIC ATROPISOMER COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-04-15 EP disclosed
WO-2019243964-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
WO-2019243964-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
US-10023534-B2 Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK BRISTOL-MYERS SQUIBB COMPANY (US) 2018-07-17 US disclosed
US-10023534-B2 Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK BRISTOL-MYERS SQUIBB COMPANY (US) 2018-07-17 US disclosed
US-10023534-B2 Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK BRISTOL-MYERS SQUIBB COMPANY (US) 2018-07-17 US disclosed
US-20170355673-A1 TRICYCLIC ATROPISOMER COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
US-20170355673-A1 TRICYCLIC ATROPISOMER COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed
US-20170355673-A1 TRICYCLIC ATROPISOMER COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 NOTUM 3959/4885UCHL1 2106/4885KDM1A 3485/4885
US-20260144788-A1 COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF PTPN6, PTPN1, PTPN11 NOTUM 3917/4885UCHL1 1938/4885KDM1A 2286/4885
US-20170355673-A1 TRICYCLIC ATROPISOMER COMPOUNDS BTK, LCK, SYK NOTUM 3244/4885UCHL1 3170/4885KDM1A 1432/4885
US-10023534-B2 Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK BTK, JAK2, SYK NOTUM 3167/4885UCHL1 3173/4885KDM1A 495/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 NOTUM 3263/4885UCHL1 693/4885KDM1A 3168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.